MULTAQ 400 MG
DRONEDARONE (DRONEDARONE HYDROCHLORIDE) : 400 MG · DIN 02330989 · SANOFI-AVENTIS CANADA INC
Health Canada status: MARKETED
What is MULTAQ?
MULTAQ 400 MG contains DRONEDARONE (DRONEDARONE HYDROCHLORIDE) : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 02330989, held by SANOFI-AVENTIS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 28-Sep-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MULTAQ used for?
Treatment of paroxysmal or persistent atrial fibrillation (AF) in sinus rhythm or intended for cardioversion, to reduce risk of cardiovascular hospitalization due to AF.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02330989 |
|---|---|
| Brand name | MULTAQ |
| Generic / active ingredient | DRONEDARONE (DRONEDARONE HYDROCHLORIDE) : 400 MG |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 400 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C01BD07 DRONEDARONE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 28-Sep-2009 |
| Original market date | 2009-10-14 00:00:00 |
How is it administered?
Recommended dose is 400 mg twice daily (one tablet with morning meal, one with evening meal). Stop Class I or III antiarrhythmics before starting.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. (Note: General pharmaceutical standard, though specific text mentions "Store at" in section 11 which is not fully detailed in the snippet, section 6 mentions core/coating).
How is it supplied?
Bottles of 60, 180, and 500 tablets; boxes of 4 blisters (15 tablets per blister).
Contraindications
Permanent AF, history of/current heart failure, LV systolic dysfunction, 2nd/3rd degree AV block, bradycardia <50 bpm, severe hepatic impairment, pregnancy, lactation, strong CYP3A4 inhibitors.
Warnings and precautions
Risk of liver injury (including fatal failure), new/worsening heart failure, interstitial lung disease, and increased risk of death/stroke in permanent AF. Monitor ECG and renal function.
What can be used instead?
Other Canadian products sharing ATC code C01BD07 DRONEDARONE. 1 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ASN-DRONEDARONE | 400 MG | TABLET | ASCEND LABORATORIES LTD | APPROVED | DIN 02514397 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.